Delving into the Latest Updates on Ofloxacin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid, floxacin and Sodium Chloride, Of1oxacin

+ [56]

Target

Bacterial DNA gyrase x Bacterial top IV

Mechanism

Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors)

Therapeutic Areas

Infectious DiseasesEye DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication

ConjunctivitisCorneal UlcerTrachoma+ [7]

Inactive Indication

Acute otitis media

Originator Organization

Daiichi Sankyo Co., Ltd.

Active Organization

Santen Pharmaceutical Co., Ltd.Allergan, Inc.

Livzon Group Livzon Pharmaceutical Factory

+ [2]

Inactive Organization

Janssen Pharmaceuticals, Inc.Daiichi Pharmaceutical Co., Ltd.

Daiichi Sankyo, Inc.

Drug Highest PhaseApproved

First Approval Date

JP (16 Apr 1985),

Bacterial InfectionsOtitis ExternaOtitis Media

RegulationOrphan Drug (US), Orphan Drug (JP)

Login to view timeline

Structure

Molecular FormulaC18H20FN3O4

InChIKeyGSDSWSVVBLHKDQ-UHFFFAOYSA-N

CAS Registry82419-36-1

This randomized controlled trial aims to evaluate the effectiveness of intravenous (IV) versus rectal acetaminophen for postoperative pain management in neonates. The study includes postoperative term neonates who require analgesia for at least 12 hours. The main questions the study seeks to answer are:
Does IV acetaminophen provide better pain relief compared to rectal administration in neonates? What is the time to rescue analgesia and the efficacy of pain score reduction between these two routes? The study compares 32 neonates receiving IV acetaminophen to 32 neonates administered rectal acetaminophen. Both routes are administered at equivalent bioavailable doses to ensure a fair comparison.

Start Date10 Jan 2023

Sponsor / Collaborator

Rawalpindi Medical College

NCT05302531 / RecruitingPhase 1IIT

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study

The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.

Start Date09 Dec 2022

Sponsor / Collaborator

Centre Hospitalier Regional de Nancy

[+1]

100 Clinical Results associated with Ofloxacin

Login to view more data

100 Translational Medicine associated with Ofloxacin

Login to view more data

100 Patents (Medical) associated with Ofloxacin

Login to view more data

7,351

Literatures (Medical) associated with Ofloxacin

01 Feb 2025·FOOD CHEMISTRY

High sensitivity distinguishing detection of fluoroquinolones with a cage-based lanthanide metal-organic framework in food

Article

Author: Jia, Lei ; Zhao, Xiaolei ; Zhao, Tongqian ; Zhao, Dan ; Xu, Jun ; Jia, Ruoqin ; Zhang, Lina ; Huang, Yuanyuan

Sensitive and selective detection of fluoroquinolones, especially from different sources, is challenging. This study reported an uncommon three-cage lanthanide metal-organic framework (1-Eu) with a Eu³⁺ cluster as its structural primitive using a C₂-symmetric 5,5-(Pyrazine-2,6-diyl) diisophthalic acid ligand. The 1-Eu probe effectively detected four fluoroquinolones through distinct color changes and spectral emission bands, demonstrating excellent performance with low detection limits: moxifloxacin (LOD: 9.3 nM), danofloxacin (LOD: 33.7 nM), gatifloxacin (LOD: 67.9 nM), and ofloxacin (LOD: 238.6 nM). Mechanistic studies revealed that internal filtration and photoinduced electron transfer (a-PET) effects were key factors. Furthermore, 1-Eu was successfully used to detect fluoroquinolones in food samples. Additionally, portable paper-based sensors were developed to quickly semi-quantify analyte concentrations using a smartphone color recognition app, underscoring the practical potential of this probe. This study introduces a novel methodology for the identification and detection of fluoroquinolones to enhance food safety.

01 Dec 2024·Journal of Global Antimicrobial Resistance

Multi-omics analysis explores the impact of ofloxacin pressure on the metabolic state in Escherichia coli

Article

Author: Feng, Miao ; Wang, Shuowen ; Yi, Xiaoyu ; He, Feng ; Yao, Hailan ; Xiao, Zonghui ; Wang, Yichuan

OBJECTIVES:

The rising threat of antibiotic resistance poses a significant challenge to public health. The research on the new direction of resistance mechanisms is crucial for overcoming this hurdle. This study examines metabolic changes by comparing sensitive and experimentally induced ofloxacin-resistant Escherichia coli (E. coli) strains using multi-omics analyses, aiming to provide novel insights into bacterial resistance.

METHODS:

An ofloxacin-resistant E. coli strain was selected by being exposed to high concentration of ofloxacin. Comparative analyses involving transcriptomics, proteomics, and acetylomics were conducted between the wild-type and the ofloxacin-resistant (Re-OFL) strains. Enrichment pathways of differentially expressed genes, proteins and acetylated proteins between the two strains were analysed using gene ontology and Kyoto Encyclopedia of Genes and Genomes method. In addition, the metabolic network of E. coli was mapped using integrated multi-omics analysis strategies.

RESULTS:

We identified significant differences in 2775 mRNAs, 1062 proteins, and 1015 acetylated proteins between wild-type and Re-OFL strains. Integrated omics analyses revealed that the common alterations enriched in metabolic processes, particularly the glycolytic pathway. Further analyses demonstrated that 14 metabolic enzymes exhibited upregulated acetylation levels and downregulated transcription and protein levels. Moreover, seven of these metabolic enzymes (fba, tpi, gapA, pykA, sdhA, fumA, and mdh) were components related to the glycolytic pathway.

CONCLUSIONS:

The changes of metabolic enzymes induced by antibiotics seem to be a key factor for E. coli to adapt to the pressure of antibiotics, which shed new light on understanding the adaptation mechanism when responding to ofloxacin pressure.

01 Dec 2024·CURRENT MICROBIOLOGY

Isolation of Sphingopyxis kveilinensis sp. nov., a Potential Antibiotic-Degrading Bacterium, from a Karst Wetland

Article

Author: Chen, Ying ; Yu, Chengjian ; Deng, Jie

A Gram-stain-negative, aerobic, mesophilic, motile, rod-shaped bacterium, designated strain TUF1^T, was isolated from a karst wetland in south-west China. It was demonstrated to be capable of growing on plates containing oxytetracycline, streptomycin, or ofloxacin as the sole carbon source. Phylogenetic analysis of the 16S rRNA gene sequence revealed that this organism belongs to the genus Sphingopyxis and is closely related to S. chilensis S37^T (99.17%) and S. alaskensis RB2256^T (99.12%). The orthologous average nucleotide identity values (OrthoANIu, 84.42% and 87.53%) and digital DNA-DNA hybridization values (dDDH, 41.7% and 48.9%) between strain TUF1^T and its close relatives were all below the standard recommended threshold values for species discrimination. The genomic DNA G + C content was determined to be 64.7%. The predominant cellular fatty acids were identified as summed feature 8 (C_18:1ω7c and/or C_18:1ω6c) and summed feature 3 (C_16:1ω7c and/or C_16:1ω6c). The major polar lipids found to be diphosphatidylglycerol, phosphatidylglycerol, phosphatidylcholine, phosphatidylethanolamine, and sphingoglycolipid. The sole respiratory quinone present was ubiquinone Q10. Based on the phylogenetic, biochemical, physiological, and chemotaxonomic analyses, strain TUF1^T represents a novel species of the genus Sphingopyxis. The designation "Sphingopyxis kveilinensis sp. nov." is proposed as the name for this novel species, and the strain TUF1^T (= CGMCC1.62043^T = JCM36394^T) is designated as the type strain.

1

News (Medical) associated with Ofloxacin

30 Jan 2023

·www.prnewswire.com

Study Concludes Enzyme-Based Advanced Formula ZYMOX® Otic Plus Beneficial

New Research Published Examines ZYMOX® Otic Plus on Canine Otitis Externa and Removal of Biofilms WESTMONT, Ill., Jan. 30, 2023 /PRNewswire/ -- PKB Animal Health, the industry leader in enzyme-based dermatology and oral care products for animals, announced the Polish Journal of Veterinary Sciences has published findings from a recent study on the effects of ZYMOX Otic Plus on canine otitis externa and removal of biofilms. The study evaluated in detail the in vivo and in vitro efficacy and concluded ZYMOX Otic Plus to be effective and beneficial for the management of canine otitis externa. Canine otitis externa is a common problem affecting a large percentage of dogs and cats, yet antibiotic resistance represents a major challenge to its treatment. While it is believed that bacteria and yeast produce biofilm structures that result in persistent conditions that are not responsive to traditional antibiotic therapeutics, ZYMOX Otic Plus contains a combination of enzymes including the biofilm-degrading enzymes mutanase and dextranase. The results of this study demonstrate the viability of ZYMOX Otic Plus as an alternative to antibiotics. Additional studies on ZYMOX efficacy have been published in the International Journal of Applied Veterinary Research on antibiofilm efficacy and a broad range of microorganisms, including Pseudomonas aeruginosa, Malassezia, and Methicillin-resistant Staphylococcus aureus (MRSA). Visit zymox.com to learn more about the Advanced Formula ZYMOX Otic Plus and the full line Dermatology products. About PKB Animal Health Pet King Brands, dba PKB Animal Health, the maker of ZYMOX® Ear and Skin products, Oratene® Brushless Oral Care, Equine Defense®, and ZYLAFEN® is a leader in veterinarian-approved pet products made in the USA. Focused on the health and wellness of small and large animals of all ages, the products utilize the Power of the LP3 Enzyme System and have been Resolving Ear, Skin, and Oral Conditions for Over 25 Years. Led by President and Founder, Pamela Bosco, who first introduced ZYMOX in 1998 with the help of her bio scientist brother, Michael Pellico, Pet King Brands has revolutionized the way people care for animals' ears, skin, and mouth offering solutions that are gentle to the animal, easy to administer and free of harsh chemicals and antibiotics. Media Contact: [email protected] SOURCE PKB Animal Health

Drug Approval

100 Deals associated with Ofloxacin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00453	Ofloxacin	S01AE01 S02AA16 J01MA01	DB01165

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Infectious Diseases	US	Daiichi Pharmaceutical Co., Ltd.	16 Dec 1997
Conjunctivitis	US	Janssen Pharmaceuticals, Inc.	28 Dec 1990
Corneal Ulcer	US	Janssen Pharmaceuticals, Inc.	28 Dec 1990
Trachoma	JP	Santen Pharmaceutical Co., Ltd.	01 Jun 1989
Blepharitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Dacryocystitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Hordeolum	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Keratitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Bacterial Infections	JP	Novartis Pharma AG	16 Apr 1985
Otitis Externa	JP	Alfresa Pharma Corp.	16 Apr 1985
Otitis Media	JP	Alfresa Pharma Corp.	16 Apr 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	Phase 3	-	Daiichi Sankyo, Inc.	01 Nov 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02528123 (CTgov)	Not Applicable	Myopia	114	Small incision lenticule extraction+Tobramycin+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+dexamethasone+Ofloxacin	kmhvkgkepw(aqmhunrvod) = lcxnpbelbo pwhwullspg (qxbskwkbdy, uqbkuxzagh - uspwqwthgn) View more	-	23 Apr 2024
NCT02567825 (CTgov)	Not Applicable	Acute otitis media	250	Tympanostomy tube placement+Ofloxacin Otic (Surgical Management)	ltxipzbbly(mgynzevmjy) = ytkfqujyyo mkjjivpafl (ucyfxnlqip, kygsmyqwnp - gnpdgggasd) View more	-	10 Dec 2021
				Ceftriaxone+Amoxicillin-Clavulanate (Non-Surgical Management)	ltxipzbbly(mgynzevmjy) = ueubijobtz mkjjivpafl (ucyfxnlqip, xdqmoxtpvm - vlkzzehezg) View more
NCT02373137 (DETECT, CTgov)	Phase 4	Corneal Diseases \| Keratoplasty rejection	38	DMEK+Tropicamide+phenylephrine+prednisolone+Ofloxacin (DMEK)	sdihnjxfgy(ekenatnjmz) = fnsvzkdomu bsxinemufn (vmeyjfhwpf, ovgumvgppo - bspwtmutln) View more	-	02 Jul 2019
				DSAEK+Tropicamide+phenylephrine+prednisolone+Ofloxacin (DSAEK)	jyslstesmo(azwxezjmzw) = sekjipifox aoakkqomsv (pfltabmpxv, croacaobza - gjzcdjkhbw) View more
AAAAI2010	Not Applicable	Hypersensitivity	-	Quinolones	tgwaworwgw(rmqbhvrlvl) = yysirkgpxr akhefncjqf (jwuvzxwebi )	Positive	01 Feb 2010
				Quinolones	tgwaworwgw(rmqbhvrlvl) = fksicszlvk akhefncjqf (jwuvzxwebi )
IAS2009	Not Applicable	Tuberculosis \| Acquired Immunodeficiency Syndrome	8	ofloxacin (Patients with multi-drug resistant tuberculosis)	hrasgkdoyy(ryexujdzaw) = xzecstvgve aexabynhzz (yaxlvhkqau ) View more	-	01 Jan 2009
				ofloxacin (Patients co-infected with multi-drug resistant tuberculosis and HIV/AIDS)	hrasgkdoyy(ryexujdzaw) = erfjxhqogu aexabynhzz (yaxlvhkqau ) View more
ISRCTN11871179 (Pubmed \| BMC Infect Dis)	Not Applicable	Brucellosis	-	Ofloxacin plus rifampicin	gxkuykacqd(niaqgymyzg) = ncorvfrxbj ntobzugfed (hohesxvyoc, 48 - 216)	-	23 Jun 2004
				Doxycycline plus rifampicin	gxkuykacqd(niaqgymyzg) = sqsnydcfqo ntobzugfed (hohesxvyoc, 48 - 262)